{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:42:39Z","timestamp":1791243759300,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Forschungsgruppe Herz-Kreislauf, e.V. (Monheim)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.prostaglandins.2015.07.004","type":"journal-article","created":{"date-parts":[[2015,7,19]],"date-time":"2015-07-19T14:01:35Z","timestamp":1437314495000},"page":"17-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"PA","title":["Aspirin and lipid mediators in the cardiovascular system"],"prefix":"10.1016","volume":"121","author":[{"given":"Karsten","family":"Schr\u00f6r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard H.","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prostaglandins.2015.07.004_bib0005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01662127","article-title":"Pharmakologisches \u00fcber Aspirin (Acetylsalizyls\u00e4ure)","volume":"76","author":"Dreser","year":"1899","journal-title":"Pfl\u00fcgers Arch. Physiol."},{"issue":"25","key":"10.1016\/j.prostaglandins.2015.07.004_bib0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat. New Biol."},{"issue":"8","key":"10.1016\/j.prostaglandins.2015.07.004_bib0015","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1073\/pnas.72.8.3073","article-title":"Acetylation of prostaglandin synthase by aspirin","volume":"72","author":"Roth","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.prostaglandins.2015.07.004_bib0020","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1086\/606060","article-title":"Salicylates and pandemic influenza mortality, 1918\u20131919 pharmacology, pathology, and historic evidence","volume":"49","author":"Starko","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.prostaglandins.2015.07.004_bib0025","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1038\/srep07896","volume":"5","author":"Wang","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prostaglandins.2015.07.004_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.2014.271","article-title":"Molecular targets of aspirin and cancer prevention","volume":"111","author":"Alfonso","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.prostaglandins.2015.07.004_bib0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1084\/jem.20040566","article-title":"15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation","volume":"200","author":"Paul-Clark","year":"2004","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.prostaglandins.2015.07.004_bib0040","doi-asserted-by":"crossref","first-page":"C557","DOI":"10.1152\/ajpcell.00045.2005","article-title":"Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells","volume":"289","author":"Nascimento-Silva","year":"2005","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"10","key":"10.1016\/j.prostaglandins.2015.07.004_bib0045","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/CIRCULATIONAHA.111.046243","article-title":"Cardiology patient page: aspirin","volume":"125","author":"Paikin","year":"2012","journal-title":"Circulation, ."},{"issue":"38","key":"10.1016\/j.prostaglandins.2015.07.004_bib0050","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur. Heart J."},{"issue":"15","key":"10.1016\/j.prostaglandins.2015.07.004_bib0055","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/jnci\/89.15.1152","article-title":"Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose","volume":"89","author":"Ruffin","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.prostaglandins.2015.07.004_bib0060","first-page":"1","article-title":"Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers","volume":"5","author":"Nagelschmitz","year":"2013","journal-title":"Clin. Pharmacol.: Adv. Appl."},{"key":"10.1016\/j.prostaglandins.2015.07.004_bib0065","first-page":"376","article-title":"Acetylsalicylic Acid","year":"2009"},{"issue":"5244","key":"10.1016\/j.prostaglandins.2015.07.004_bib0070","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1126\/science.270.5244.2017","article-title":"The effect of sodium salicylate and aspirin on NF-kappa B","volume":"270","author":"Frantz","year":"1995","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.prostaglandins.2015.07.004_bib0075","doi-asserted-by":"crossref","first-page":"184","DOI":"10.7326\/0003-4819-120-3-199402010-00002","article-title":"Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury","volume":"120","author":"Lee","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.prostaglandins.2015.07.004_bib0080","first-page":"1","article-title":"Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers","volume":"5","author":"Nagelschmitz","year":"2013","journal-title":"Clin. Pharmacol. Adv. Appl."},{"issue":"3","key":"10.1016\/j.prostaglandins.2015.07.004_bib0085","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1096\/fj.05-4434fje","article-title":"Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2","volume":"20","author":"Warner","year":"2006","journal-title":"FASEB J."},{"issue":"12","key":"10.1016\/j.prostaglandins.2015.07.004_bib0090","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/01.CIR.0000142056.69970.DB","article-title":"Terms and conditions: semantic complexity and aspirin resistance","volume":"110","author":"Hennekens","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.prostaglandins.2015.07.004_bib0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/bmm.10.122","article-title":"Functional testing methods for the antiplatelet effects of aspirin","volume":"5","author":"Schr\u00f6r","year":"2011","journal-title":"Biomark. Med."},{"issue":"4","key":"10.1016\/j.prostaglandins.2015.07.004_bib0100","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.thromres.2013.01.033","article-title":"New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals","volume":"131","author":"Kovacs","year":"2013","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.prostaglandins.2015.07.004_bib0105","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.prostaglandins.2015.07.004_bib0110","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1160\/TH12-07-0532","article-title":"High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs\u2013pharmacological mechanisms and clinical relevance","volume":"109","author":"Hohlfeld","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.prostaglandins.2015.07.004_bib0115","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jacc.2013.07.039","article-title":"Dipyrone (metamizole) can nullify the antiplatelet effect of aspirin in patients with coronary artery disease","author":"Polzin","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2015.07.004_bib0120","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1160\/TH10-02-0082","article-title":"24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease","volume":"105","author":"Henry","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.prostaglandins.2015.07.004_bib0125","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ahj.2012.06.008","article-title":"Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease","volume":"164","author":"Dillinger","year":"2012","journal-title":"Am. Heart J."},{"issue":"3","key":"10.1016\/j.prostaglandins.2015.07.004_bib0130","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1172\/JCI110814","article-title":"Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man","volume":"71","author":"FitzGerald","year":"1983","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.prostaglandins.2015.07.004_bib0135","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1172\/JCI109379","article-title":"Inhibition of prostacyclin by treatment of endothelium with aspirin. Correlation with platelet adherence","volume":"63","author":"Czervionke","year":"1979","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.prostaglandins.2015.07.004_bib0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.CIR.79.1.29","article-title":"In vivo measurement of thromboxane B2 and 6-keto-prostaglandin F1 alpha in humans in response to a standardized vascular injury and the influence of aspirin","volume":"79","author":"Gerrard","year":"1989","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.prostaglandins.2015.07.004_bib0145","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.96.1.272","article-title":"Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2","volume":"96","author":"McAdam","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"43","key":"10.1016\/j.prostaglandins.2015.07.004_bib0150","doi-asserted-by":"crossref","first-page":"17597","DOI":"10.1073\/pnas.1209192109","article-title":"Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system","volume":"109","author":"Kirkby","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.prostaglandins.2015.07.004_bib0155","doi-asserted-by":"crossref","first-page":"E183","DOI":"10.1073\/pnas.1219073110","article-title":"COX-2, the dominant source of prostacyclin","volume":"110","author":"Ricciotti","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"132","key":"10.1016\/j.prostaglandins.2015.07.004_bib0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003787","article-title":"Vascular COX-2 modulates blood pressure and thrombosis in mice","volume":"4","author":"Yu","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.prostaglandins.2015.07.004_bib0165","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.CIR.102.8.840","article-title":"Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis","volume":"102","author":"Belton","year":"2000","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.prostaglandins.2015.07.004_bib0170","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1046\/j.1538-7836.2003.00304.x","article-title":"The evolving role of platelets in inflammation","volume":"1","author":"Weyrich","year":"2003","journal-title":"J. Thromb. Haemost."},{"issue":"14","key":"10.1016\/j.prostaglandins.2015.07.004_bib0175","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.prostaglandins.2015.07.004_bib0180","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1160\/TH09-03-0177","article-title":"Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients","volume":"103","author":"Muhlestein","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.prostaglandins.2015.07.004_bib0185","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-2125.2011.03906.x","article-title":"Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation","volume":"72","author":"Passacquale","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2015.07.004_bib0190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ccr.2012.11.013","article-title":"Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer","volume":"23","author":"Liang","year":"2013","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.prostaglandins.2015.07.004_bib0195","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nri2974","article-title":"The outs and the ins of sphingosine-1-phosphate in immunity","volume":"11","author":"Spiegel","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.prostaglandins.2015.07.004_bib0200","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1538-7836.2011.04194.x","article-title":"Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation","volume":"9","author":"Ulrych","year":"2011","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.prostaglandins.2015.07.004_bib0205","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1189\/jlb.3AB1013-567R","article-title":"Sphingosine-1-phosphate induces thrombin receptor PAR-4 expression to enhance cell migration and COX-2 formation in human monocytes","volume":"96","author":"Mahajan-Thakur","year":"2014","journal-title":"J. Leukocyte Biol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2015.07.004_bib0210","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ijcard.2013.10.050","article-title":"Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction","volume":"170","author":"Polzin","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.prostaglandins.2015.07.004_bib0215","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev.immunol.25.022106.141647","article-title":"Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways","volume":"25","author":"Serhan","year":"2007","journal-title":"Annu. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.prostaglandins.2015.07.004_bib0220","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCRESAHA.110.223883","article-title":"Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins","volume":"107","author":"Spite","year":"2010","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.prostaglandins.2015.07.004_bib0225","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-5793(94)80579-2","article-title":"Mutation of serine-516 in human prostaglandin G\/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis","volume":"342","author":"Mancini","year":"1994","journal-title":"FEBS Lett."},{"issue":"18","key":"10.1016\/j.prostaglandins.2015.07.004_bib0230","doi-asserted-by":"crossref","first-page":"13207","DOI":"10.1016\/S0021-9258(17)36820-5","article-title":"Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin","volume":"269","author":"Lecomte","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.prostaglandins.2015.07.004_bib0235","doi-asserted-by":"crossref","first-page":"9475","DOI":"10.1073\/pnas.92.21.9475","article-title":"Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions","volume":"92","author":"Claria","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.prostaglandins.2015.07.004_bib0240","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/S0021-9258(18)53294-4","article-title":"Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs","volume":"268","author":"Meade","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.prostaglandins.2015.07.004_bib0245","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1124\/mol.51.1.52","article-title":"Altered sensitivity of aspirin-acetylated prostaglandin G\/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs","volume":"51","author":"Mancini","year":"1997","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2015.07.004_bib0250","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.4049\/jimmunol.0900477","article-title":"Effects of low-dose aspirin on acute inflammatory responses in humans","volume":"183","author":"Morris","year":"2009","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2015.07.004_bib0255","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.bjp.0705907","article-title":"Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action","volume":"143","author":"Taubert","year":"2004","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.prostaglandins.2015.07.004_bib0260","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCRESAHA.110.222968","article-title":"Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase","volume":"107","author":"Jung","year":"2010","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.prostaglandins.2015.07.004_bib0265","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0006-291X(03)01504-3","article-title":"Heme oxygenase-1 induction may explain the antioxidant profile of aspirin","volume":"308","author":"Grosser","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.prostaglandins.2015.07.004_bib0270","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/01.ATV.0000083296.57581.AE","article-title":"Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway","volume":"23","author":"Grosser","year":"2003","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.prostaglandins.2015.07.004_bib0275","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/01.CIR.97.8.716","article-title":"Aspirin improves endothelial dysfunction in atherosclerosis","volume":"97","author":"Husain","year":"1998","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.prostaglandins.2015.07.004_bib0280","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0008-6363(98)00013-3","article-title":"Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin","volume":"38","author":"Noon","year":"1998","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.prostaglandins.2015.07.004_bib0285","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1074248410375091","article-title":"A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans","volume":"15","author":"Hennekens","year":"2010","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.prostaglandins.2015.07.004_bib0290","doi-asserted-by":"crossref","DOI":"10.1177\/1074248413482753","article-title":"Aspirin increases nitric oxide formation in chronic stable coronary disease","volume":"18","author":"Hetzel","year":"2013","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"9826","key":"10.1016\/j.prostaglandins.2015.07.004_bib0295","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.prostaglandins.2015.07.004_bib0300","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1160\/TH13-04-0326","article-title":"Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation","volume":"110","author":"Cea Soriano","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.prostaglandins.2015.07.004_bib0305","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1111\/j.1572-0241.2008.02216.x","article-title":"ACCF\/ACG\/AHAexpert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use","volume":"103","author":"Bhatt","year":"2008","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2015.07.004_bib0310","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mdu225","article-title":"Estimates of benefits and harms of prophylactic use of aspirin in the general population","volume":"26","author":"Cuzick","year":"2014","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.prostaglandins.2015.07.004_bib0315","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"Simes","year":"2014","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.prostaglandins.2015.07.004_bib0320","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7326\/0003-4819-158-11-201306040-00004","article-title":"Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial","volume":"158","author":"Anderson","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"11","key":"10.1016\/j.prostaglandins.2015.07.004_bib0325","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/M14-1884","article-title":"Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U. S. preventive services task force recommendation statement","volume":"161","author":"LeFevre","year":"2014","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.prostaglandins.2015.07.004_bib0330","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1940-6207.CAPR-11-0391","article-title":"Aspirin in the chemoprevention of colorectal neoplasia: an overview","volume":"5","author":"Chan","year":"2011","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"10.1016\/j.prostaglandins.2015.07.004_bib0335","article-title":"Circulating prostaglandin biosynthesis in colorectal cancer and potential clinical significance","author":"Li","year":"2014","journal-title":"EBioMedicine"}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882315300058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882315300058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T14:28:59Z","timestamp":1652884139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882315300058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":67,"alternative-id":["S1098882315300058"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2015.07.004","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin and lipid mediators in the cardiovascular system","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2015.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}